Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/II multicenter, multi-arm, randomized, double-blind and placebo-controlled trial of vafidemstat in Kabuki syndrome patients

Next Previous
X
Search
Trial Profile

Phase I/II multicenter, multi-arm, randomized, double-blind and placebo-controlled trial of vafidemstat in Kabuki syndrome patients

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 25 Oct 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vafidemstat (Primary)
  • Indications Kabuki syndrome
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms HOPE
  • Sponsors Oryzon

    • Most Recent Events

    • 24 Oct 2024 According to an Oryzon media release, the company will decide on a possible submission of an IND for HOPE to the FDA in 2025
    • 27 Oct 2023 According to an Oryzon media release, the company is in a dialogue with the regulatory agencies to refine the final design of this trial and expects to submit an IND for HOPE to the U.S. Food and Drug Administration (FDA) in 2024.
    • 27 Oct 2023 According to an Oryzon media release, the company is expecting to initiate this trial in 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top